Adeno-associated virus (AAV)-mediated gene replacement for lysosomal disorders have been spurred by the ability of some serotypes to efficiently transduce neurons in the brain and by the ability of lysosomal enzymes to cross-correct among cells. Here, we explored enzyme replacement therapy in a knock-out mouse model of congenital neuronal ceroid lipofuscinosis (NCL), the most severe of the NCLs in humans. The missing protease in this disorder, cathepsin D (CathD) has high levels in the central nervous system. This enzyme has the potential advantage for assessing experimental therapy in that it can be imaged using a near-infrared fluorescence (NIRF) probe activated by CathD. Injections of an AAV2/rh8 vector-encoding mouse CathD (mCathD) into both cerebral ventricles and peritoneum of newborn knock-out mice resulted in a significant increase in lifespan. Successful delivery of active CathD by the AAV2/rh8-mCathD vector was verified by NIRF imaging of mouse embryonic fibroblasts from knock-out mice in culture, as well as by ex vivo NIRF imaging of the brain and liver after gene transfer. These studies support the potential effectiveness and imaging evaluation of enzyme replacement therapy to the brain and other organs in CathD null mice via AAV-mediated gene delivery in neonatal animals.
INTRODUCTION
Lysosomal storage diseases comprise over 40 genetic deficiency states involving accumulation of undegraded gangliosides, lipids, oligosaccharides and proteins in tissues throughout the body, with a collective incidence of 1/7500 in the population. 1,2 Many of these diseases have a predominant neurodegenerative phenotype leading to loss of mental functions and early death, such as Tay-Sachs disease. 3 The neuronal ceroid lipofuscinoses (NCLs) are a subtype of lysosomal storage diseases typically with neurodegenerative onset in childhood and accumulation of autofluorescent storage material such as lipofuscin in multiple tissues. As of 2005, six genes had been identified as underlying different forms of this condition. 4 In 2006, two groups identified disruptive mutations in the gene for the protease cathepsin D (CathD), as the underlying autosomal recessive defect in most cases of severe, congenital NCL in humans. 5, 6 This lysosomal aspartyl endopeptidase is present in most tissues, with particularly high levels in the brain. 7, 8 This deficiency state had previously been characterized in several naturally occurring animal models, including sheep 9 and dogs. 10, 11 A knock-out mouse model of CathD deficiency develops seizures, blindness, thromboemboli, lymphopenia and intestinal necrosis, with death occurring around post-natal day 26. [12] [13] [14] Gene therapy using viral vectors to deliver the missing enzyme directly into the brain has proven to be very promising in experimental models of a number of lysosomal storage diseases 15, 16 taking advantage of cross-correction, whereby normal cells release the deficient enzyme for uptake by endogenous deficient cells. 17 ProCathD is secreted from cells and can be taken up via the mannose-6-phosphate receptors for incorporation into lysosomes. 18 Adeno-associated viral (AAV) vector-mediated gene delivery to the central nervous system has proven highly effective in a large number of small and large animal models of lysosomal storage diseases with neurological involvement. 15, 16 The ability to achieve widespread, sustained gene delivery to the brain using AAV vectors, combined with their low-to-no toxicity, has supported their use in clinical trials for enzyme replacement in Canavan's disease, 19 as well as infantile and late infantile NCL 20, 21 (for review see Wong et al. 22 ).
New molecular imaging modalities provide the opportunity to image pathogenic mechanisms, gene delivery and therapeutic response in the brain and other tissues. 23 In particular, near-infrared fluorescence (NIRF) allows imaging of protease activity in cells using probes in which a fluorochrome emitting in the infrared range (with high tissue penetrance) is quenched by its positioning along a polylysine polymer through linkage to a protease peptide substrate, with cleavage of the peptide producing a marked increase in fluorescence. 24 This imaging modality has been used to monitor the activity of cathepsins in tumors, 25, 26 viral proteases associated with vector delivery, 27 matrix metalloproteinases in metastatic tumor foci 28 and caspases during apoptosis. 29, 30 This study focuses on gene delivery of CathD to a knock-out mouse model of congenital NCL. Intracranial and intraperitoneal (i.p.) injections of AAV2/rh8 vectors encoding mouse CathD (mCathD) were performed in newborn pups. Successful gene replacement was observed by extended survival times and expression of CathD activity in cells and tissues as detected by CathD-specific NIRF imaging.
RESULTS
Generation and characterization of AAV vector-encoding mCathD mCathD complementary DNA was cloned into an AAV vector plasmid under the control of the chicken beta-actin promoter (pAAV-mCathD; Figure 1a ). As a control, a similar vector was generated expressing enhanced GFP under the same promoter (pAAV-GFP). To test for vector-mediated mCathD expression, fibroblasts from homozygous CathD knock-out embryos were transiently transfected with the pAAV-mCathD or pAAV-GFP plasmid and western blot analysis was performed on cell lysates 48 h later. In cells transfected with pAAVmCathD, a double band was observed around 50 kDa corresponding to a short-lived precursor form (53 kDa) and the intermediate form (47 kDa) of CathD, as well as a band at 30 kDa corresponding to the mature form of CathD 31 ( Figure 1b) . None of these bands were observed in lysates from knock-out cells transfected with pAAV-GFP.
In order to image vector-mediated CathD expression, wild-type mouse fibroblasts, knock-out fibroblasts, as well as knock-out fibroblasts transfected with pAAV-GFP or both pAAV-mCathD and pAAV-GFP plasmids were incubated with a Cy5.5-CathD-specific NIRF probe (200 nM for 60 min) and analyzed by fluorescence-activated cell sorting for Cy5.5 fluorescence. The knock-out fibroblasts showed very minimal signal, whereas the wild-type fibroblasts showed intense Cy5.5 fluorescence, indicating that the probe was cleaved and activated in the presence of CathD in these cells (Figure 2 ). Knock-out cells cotransfected with both pAAV-mCathD and pAAV-GFP plasmids showed an increase in Cy5.5 fluorescence intensity (all GFP-positive cells were also Cy5.5 positive), as compared with cells transfected with pAAV-GFP plasmid alone, which showed no signal (Figure 2 ). These results prove that CathD gene delivery can be monitored using NIRF imaging and that the mature form of CathD is active in these cells.
Extended lifespan of knock-out mice injected with AAV2/rh8 mCathD vector In order to check whether mCathD gene delivery to the brain could impact survival, knock-out mice received intracerebroventricular (i.c.v.) injection at post-natal day 1 (P1; n¼16) or P4 (n¼6) with either phosphate-buffered saline (PBS) (control) or 2Â10 10 genome copies (g.c.) of AAV2/rh8-mCathD in each ventricle. We have previously shown that this dose of AAV2/rh8 vector yields widespread gene delivery in neonatal mouse brain. 32, 33 Time of death was recorded. There was no significant survival benefit among the two groups (data not shown). Since loss of function of CathD in humans and mice results in death-related changes in both the brain (microcephaly, seizures) and peripheral tissues (respiratory insufficiency, massive intestinal necrosis, thromboemboli and lymphopenia), we decided to perform both cerebral ventricular, as well as i.p. injections. Neonatal pups were injected on P1 (n¼2), P2 (n¼4) or P4 (n¼4; total n¼10) with both i.c.v. (2Â10 10 g.c. in 2 ml 0.06% Trypan blue to each ventricle) and i.p. (1Â10 10 g.c. in 100 ml) of AAV2/rh8-mCathD vector. Similar group of mice were injected with PBS as a control and time of death was recorded. Control knock-out mice had an average lifespan of 29.1 (s.e. ± 0.6 days; range, 26-32 days, n¼10) consistent with previous studies. 12 AAV2/rh8-mCathD vector-injected knock-out mice had a significantly longer average lifespan of 35.4 days (s.e. ± 2.1 days; range, 29-49 days, n¼10; Figure 3a ). No differences were seen between mice injected at different post-natal days. Knockout mice injected with the AAV2/rh8-GFP control vector had a similar lifespan as PBS-injected mice, whereas injected heterozygous and wild-type littermates were healthy and lived for about 2 years (data not shown). In a parallel experiment, AAV2/rh8-mCathDinjected knock-out mice were killed at P27. Brains were removed from these mice and other knock-out, heterozygous and wild-type mice, lysed and analyzed by western blotting. A double band around 50 kDa corresponding to the short lived and intermediate form of CathD as well as two bands at 31 and 14 kDa corresponding to the mature fragments was observed in brain lysates from knock-out mice injected with AAV2/rh8-mCathD, but not in non-injected knock-out mice, showing efficient CathD gene expression in the brain (Figure 3b ). The same bands were observed in lysates from heterozygous and wild-type brains.
Imaging of CathD gene replacement ex vivo with NIRF probe Neonatal CathD pups from heterozygous mating were injected with either AAV2/rh8-mCathD vector at post-natal day 1 (as above). On post-natal day 24 (2-3 days before average time of mortality in knock-out animals), AAV2/rh8-mCathD or PBS-treated knock-out mice (n¼6) were injected i.p. with the CathD-specific NIRF probe (0.1 nmoles g À1 body weight) and killed 24 h later by perfusion with PBS. Liver, brain, heart, spleen and kidneys were removed and rinsed in PBS before imaging. Organs were imaged using a custom-built camera system 34 followed by image analysis using Kodak Digital Science 1D software (Kodak, Rochester, NY, USA) ( Figure 4a) . A significant increase (four-fold; Po0.00001; Student's t-test) in Cy5.5 fluorescence signal in the brains of homozygous knock-out mice injected with AAV2/rh8-mCathD vector was observed as compared with PBS-injected knock-out mice (Figure 4b ). Signal in the livers of injected mice was B1.5-fold higher than controls (*Po0.0001). No significant increase in signal was seen in the heart, kidneys or spleen of treated mice compared with PBS control animals.
In a parallel experiment, we attempted to image CathD expression in the brain non-invasively in vivo using planar fluorescence imaging with normalized data at different time points (2-24 h) after injection of the NIRF probe as described. 35, 36 Unfortunately, we could not detect significant increase in Cy5.5 levels between knock-out mice injected with AAV2/rh8-mCathD vector at P1 and with the NIRF probe at P24, as compared with PBS-treated mice (n¼4) presumably due to the low sensitivity of the imaging system and the diffuse expression of the enzyme in the brain. Time of death was recorded. The data are presented as a Kaplan-Meier survival curve of CathD knock-out mice from both groups using JMP software. Log-rank, as well as Wilcoxon's test was performed to compare mean survival of AAV2/rh8-mCathD-treated mice versus PBS control knock-out mice and the extension of survival by treatment with AAV2/rh8-mCathD was significant (log-rank Pp0.02; Wilcoxon Pp0.05). The same experiment was repeated three times and similar results were obtained. (b) Neonatal pups were injected with AAV2/rh8-mCathD at P1 as in a and killed at P27. Brain from these mice as well as from non-injected knock-out, heterozyous and wild-type mice were removed, lysed and 50 mg protein was analyzed by western blotting for mCathD expression. The short-lived 53 kDa precursor of CathD is processed into the 47 kDa intermediate form and the mature enzyme composed of 31 and 14 kDa fragment. Similar groups of mice were injected with PBS (n¼6 per group). On P24 (2-3 days before mortality in knock-out animals), mice were injected i.p. with NIRF probe (0.1 nmoles g À1 body weight) and killed 24 h later with PBS perfusion. Liver, brain, heart, spleen and kidneys were removed, rinsed with PBS, and imaged at five different regions of interests using a custombuilt camera system followed by image analysis using Kodak Digital Science 1D software (b). 
DISCUSSION

Relevance of findings
This is the first report of experimental gene therapy for congenital NCL, which is a severe, early onset disorder causing neuronal degeneration. An AAV2/rh8 vector encoding the replacement enzyme CathD under a strong constitutive promoter was able to express active enzyme in cultured embryonic fibroblasts from knock-out mice, as well as in the brain and liver from these mice after combined infusion into the brain lateral ventricles and systemic administration (i.p.) in the perinatal period. Although the mice were not completely cured, gene delivery was effective in expanding the lifespan of these knockout mice significantly using a single i.c.v. and i.p. injection of 10 10 g.c. Systemic injection of knock-out mice with a higher dose of this AAV vector could potentially increase their survival even further. The advantage of CathD in this paradigm is that activity can be visualized and quantitated by NIRF imaging in cells and tissues using probes that have been shown to penetrate the brain efficiently. 37, 38 These studies support the feasibility of AAV-mediated gene delivery for enzyme replacement in lysosomal storage disorders, which affect the nervous system. Further, they illustrate a paradigm for potential monitoring of enzyme activity in vivo using an enhanced and more sensitive imaging system that is clinically compatible.
Gene therapy for lysosomal storage diseases
Experimental approaches to neuropathic lysosomal storage diseases include gene therapy and stem cell therapy. Of the gene therapy vectors, AAV has been translated into clinical trials for these diseases and has several advantages. These vectors can be injected directly into the brain parenchyma where they, as well as the enzymes encoded in them, can be transported over long distances via retrograde axonal transport to structures that send afferent connections to vectortransduced areas. 39, 40 Neonatal i.c.v. delivery of AAV vectors, as used in this study, has proven highly efficient in mouse models of neuropathic lysosomal storage diseases, taking advantage of either interstitial fluid flow or CSF flow for distribution of lysosomal enzymes throughout the central nervous system. 33, 41, 42 This approach is appealing for translation into humans as the neurosurgical procedure involved with ICV delivery of AAV vectors should be similar to placement of shunts in the lateral ventricles, a procedure carried out routinely in children to prevent hydrocephalus. 43 Intrathecal delivery of AAV vectors has also proven very efficient for global delivery of lysosomal enzymes to the central nervous system. 44 AAV vectors are by far the most widely used for gene delivery to the central nervous system in the experimental setting in the laboratory and also for clinical translation into humans as they mediate long-term gene expression (up to 96 weeks in humans) 45 with no apparent toxicity. The increasing number of AAV serotypes and chimeric capsids provides future opportunities for more extensive delivery of genes to the brain, even across the blood-brain barrier. 46 Presently, we do not know the exact cause of death of AAVtreated knock-out mice, but given that this enzyme is expressed throughout the body and that symptoms of CathD deficiency are widespread, we speculate that this may be due to insufficient replacement of CathD in multiple tissues throughout the body.
Imaging gene delivery Molecular imaging allows a visual (often quantitative) representation of molecular, cellular, biochemical and physiological processes in a living organism. Optical imaging, in particular fluorescence imaging, provides a facile and rapid way to image specific molecular events in vivo. Fluorescent probes emitting in the near-infrared spectrum offer the advantages of deeper tissue penetration, as there is minimal hemoglobin absorption, and improved signal-to-background ratio as autofluorescence from non-target tissues is low. Recently, NIRF fluorochrome coupled to quenching peptides, which are cleaved in response to activation of different enzymes have been used successfully for the detection of several proteases, such as cathepsins and caspases. 29, [47] [48] [49] These probes have been used both in pre-clinical and clinical trials (http://clinicaltrials.gov/ct2/results?term¼Neuronal+ceroid+ lipofuscinosis+Gene+therapy). Although in this study, we could not image expression of CathD in the brain in vivo, we were able to detect the signal in tissues ex vivo after in vivo delivery. Advancement in the field of fluorescence imaging by developing more sophisticated instrumentation and reconstruction methods should allow detection of CathD activity in the future. Recently, state-of-the-art hybrid imaging systems for Fluorescence and X-Ray Tomography (FMT-XCT) can reconstruct and co-register in 3D both the anatomical and the functional information. This improvement in fluorescence 3D imaging has been demonstrated using a near-infrared probe to target the amyloid-beta plaques in the brains of mice models in Alzheimer's disease. 50 Implications for future Gene therapy for metabolic deficiency states appears especially promising for diseases in which cross-correction is possible, as gene delivery in vivo is intrinsically limited to a subpopulation of cells. Further, in the case of lysosomal storage diseases, it appears that restoration of even 10% of enzyme activity can have marked therapeutic efficacy in animal models. Direct gene delivery to the brain is important in diseases affecting the nervous system as entry into the brain from the periphery is limited by the blood-brain barrier. In particular, AAV vectors are useful in this context as they have lowto-no toxicity, are stable and have a small size allowing spread within tissues, with some serotypes preferentially infecting neurons. Early intervention is considered critical to protecting the brain from neurodegenerative changes. Use of replacement enzymes for which activity can be measured in living cells and in vivo using new molecular imaging methods will provide the opportunity to optimize delivery systems. The present study provides a basis for further consideration of gene therapy for congenital NCL.
MATERIALS AND METHODS
Generation of AAV vector
An AAV vector, pAAV-mCathD, was derived from the plasmid pAAV-chicken beta-actin-MBG-W 32 by removing the MBG cassette and replacing it with the mCathD complementary DNA (1893 bp) excised from a pBluescript clone (ATCC (Manassas, VA, USA) construct CD-3a, number 63 114). mCathD was placed under the control of the strong, constitutive hybrid cytomegalovirus enhancer/chicken beta-actin promoter. 51 A similar vector expression GFP (pAAV-GFP) was used as a control. 32 AAV2/rh8 vectors were produced by co-transfection of 293T cells by calcium phosphate precipitation of vector plasmid (pAAV-mCathD), a mini-adenovirus helper plasmid pFD6 (from Dr Weidong Xiao, University of Pennsylvania Medical Center, Philadelphia, PA, USA), and AAVrh8 helper plasmid pAR8. 32 AAV2/rh8 vectors were purified and titered, as described 32 yielding typical titers of 2.8Â10 14 g.c. per ml.
Source and breeding of CathD knock-out mice
The CathD knock-out line was obtained from Dr Paul Saftig (University Kiel, Kiel, Germany) via Dr Hidde Ploegh (Harvard Medical School). Mice heterozygous for the disrupted CathD gene contain a neomycin cassette insertion in exon 4. 12 Mice homozygous for the mutation were generated by breeding heterozygous mice yielding a frequency of B25% affected pups per litter. Mice were genotyped at 3 weeks of age by PCR of tail clip DNA using two sets of primers in parallel. MCD14 (5¢-AGACTAACAGGCCTGTTCCC-3¢) and MCD15 (5¢-TCAGCTGTAGTTGCTCACATG-3¢), and AK30 (5¢-CGGATCA AGCGTATGCAGCCG-3¢) and AK31 (5¢-CAAGATGGATTGCACGCAGG-3¢). 52 MCD14 and MCD15 amplify a 200 bp fragment inside the wild-type allele and a 1400-bp fragment in the mutant allele. AK30 and AK31 amplify a 400-bp fragment within the wild-type allele.
Generation and cell culture of mouse embryonic fibroblasts
Mouse embryonic fibroblasts, homozygous and heterozygous for the mutant CathD gene, were generated from E17 embryos, as described. 53 These cells spontaneously immortalized and were grown in Dulbecco's-modified Eagle's medium supplemented with 10% fetal bovine serum (Sigma, St Louis, MO, USA), 100 U penicillin and 0.1 mg per ml streptomycin (Sigma), at 37 1C in a 5% CO 2 in a humidified atmosphere.
SDS-gel electrophoresis and western blotting
Cells were transiently transfected with DNA expression constructs using the calcium phosphate transfection method. Forty-eight h post-transfection, total cell lysates were prepared by washing the cells twice with PBS and resuspending the cell pellet in lysis buffer containing 50 mM Tris-HCL, pH 7.4, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EGTA, 1 mM phenylmethylsulphonyl fluoride 1 mg ml À1 pepstatin, 1 mM Na3Vo4, 1 mM NaF, 10% NP-40 and protease inhibitors (PI Complete; Roche Diagnostics, Indianapolis, IN, USA). Lysates from mice brain were prepared by homogenizing brains using a pellet pestle motor (Sigma-Aldrich, St Louis, MO, USA) in 300 ml of M-PER mammalian protein extraction reagent (Thermo Scientific, Waltham, MA, USA). A volume of 50 mg protein was resolved by electrophoresis in a 4-20% gradient SDSpolyacrylamide gel. Proteins were transferred electrophoretically to nitrocellulose (Bio-Rad, Hercules, CA, USA) and stained for protein with 0-2% Ponceau S (Sigma). The membrane was blocked over night in 5% non-fat milk powder in Tris-buffered saline with Tween (150 mm NaCl, 50 mM Tris, pH 8, 0.1% Tween). The blot was probed with an antibody against CathD (Santa Cruz Biotechnologies, Inc., Santa Cruz, CA, USA; SC-6486) diluted 1:100 in 5% milk in Trisbuffered saline with Tween, or beta-actin followed by secondary antibody conjugated to horse radish peroxidase diluted 1:2500 in 5% milk in Tris-buffered saline with Tween (Sigma) and visualized with Super Signal West Pico Chemiluminescent Substrate (Pierce Biotechnology, Rockford, IL, USA).
Fluorescence-activated cell sorting analysis
CathD knock-out mouse embryonic fibroblasts were transfected with either pAAV-GFP (3 mg) or both pAAV-mCathD (3 mg) and pAAV-GFP (1 mg) plasmids using Lipofectamine (Invitrogen, Carlsbad, CA, USA). After 48 h, these cells and wild-type mouse embryonic fibroblasts were treated for 1 h at 37 1C with 200 nM of a cyanine Cy5.5-CathD NIRF probe. 26 Cells were washed once with PBS, then aspirated and resuspended in PBS and analyzed for both GFP and NIRF fluorescence using a FACS-Calibur cytometer (Becton Dickinson, San Jose, CA, USA).
Vector injections into mice and survival curves
Heterozygous CathD knock-out mice were mated and neonatal pups were cryoanesthetized on post-natal day 1-4 (P1-4). Pups were injected with 2 ml viral vector (2Â10 10 g.c. in 0.06% Trypan blue) into each of the cerebral ventricles using a glass micropipette (70-100 mm in diameter) and a Narishige IM300 microinjector (Narishige, Tokyo, Japan). Trypan blue allowed us to visualize the ventricles being filled with the virus. The same mice were also i.p. injected with 100 ml (1Â10 10 g.c.) of the same viral vector using a 1 ml syringe and 30-gauge needle as a control, mice received similar injections of PBS only. Mice were then placed on a warming pad and returned to the mothers after regaining normal color and full activity typical of newborn mice. Mice were genotyped at B3 weeks of age and knockouts observed for onset and progression of symptoms and date of death. Uninjected mice were also observed in parallel. The experimental protocol was approved by the Institutional Animal Care and Use Committee at Massachusetts General Hospital and followed guidelines set forth in the National Institute of Health Guide for the Care and Use of Laboratory Animals. Survival data were analyzed using a Kaplan-Meier plot. Statistical evaluation was performed using JMP statistical software (SAS Institute Inc., Cary, NC, USA) with the significance calculated by log-rank.
CathD NIRF imaging
Pups from mating of heterozygous CathD knock-out mice were injected i.c.v. and i.p. with AAV2/rh8-mCathD or PBS on P1, as above (n¼6). On P24, AAV-mCathD-treated and control mice were injected i.p. with the NIRF probe (0.1 nmoles g À1 body weight) and killed 24 h later by perfusion with PBS. Liver, brain heart, spleen and kidneys were removed and rinsed in PBS before imaging. Organs were imaged using a custom-built camera system 34 at five defined regions of interest in each organ followed by image analysis using Kodak Digital Science 1D software.
